Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

Overview of attention for article published in Frontiers in oncology, March 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 2,087 followers.

#Adverse #Events Following Administration of Anti-#CTLA4 Antibody #Ipilimumab (followed by Marc #Lacroix, #Wallonia) https://t.co/ArC655NbI7

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab https://t.co/5cmgxPIyM6

New article: Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab https://t.co/jztVmMFFf5 #melanoma #oncology https://t.co/gpPbPTKl5N

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.